Diabetic Nephropathy Market
Number of pages: 100 | Report Format: PDF | Published date: December 15, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 2.23 billion |
|
Revenue forecast in 2030 |
US$ 3.25 billion |
|
Growth Rate |
CAGR of 4.3% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
Drug Class, Distribution Channel, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global diabetic nephropathy market was pegged at US$ 2.23 billion in 2021 and is expected to register a revenue CAGR of 4.3% to reach US$ 3.25 billion by 2030.
Market Fundamentals
Diabetic nephropathy is diabetes-related kidney damage or blockage. It is a disease that affects the distal convoluted tubule of the kidney and is one of the most severe issues among diabetic patients. Diabetes nephropathy may also cause miscarriage in pregnant women. Hypertension, or high blood pressure, is one of the most common factors that contribute to diabetic nephropathy. The major side effects of chronic diabetic nephropathy are progressive proteinuria, renal function failure, hypertension, and an increased risk of cardiovascular diseases. Controlling blood pressure (BP) is important for slowing the progression of diabetic nephropathy.
[35323423]
Market Dynamics
The global diabetic nephropathy market revenue growth is driven by the increasing prevalence of diabetes, the growing geriatric population, and the rising cases of obesity. Additionally, promising drugs in the pipeline and increasing investment in research & development for diabetic nephropathy drugs are contributing to the revenue growth of the global diabetic nephropathy market. Moreover, rising awareness about diabetic nephropathy and increasing government initiatives are also supporting the revenue growth of the global diabetic nephropathy market. However, the imposition of strict regulation by regulatory bodies and the high cost of research and development are expected to restrain the market revenue growth.
Market Ecosystem
The global diabetic nephropathy market has been analyzed from three perspectives: drug class, distribution channel, and region.
Diabetic Nephropathy Market by Drug Class
[24242]
Based on drug class, the global diabetic nephropathy market is segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists, and others.
The ACE inhibitors segment accounts for the largest revenue share in the global diabetic nephropathy market revenue. The large revenue share of this segment is attributed to their high therapeutic effect, low-cost of drugs, and increasing development of diabetic nephropathy in diabetics with poorly managed hyperglycemia. Additionally, Angiotensin-converting enzyme (ACE) inhibitors help in delaying the onset and slowing the progression of diabetic nephropathy and are expected to support the revenue growth of the segment.
Diabetic Nephropathy Market by Distribution Channel
Based on the distribution channel, the global diabetic nephropathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacy segment is the leading distribution channel in the global diabetic nephropathy market owing to the increasing prevalence of diabetes and diabetic nephropathy, which needs medical attention and hospitalization for treatment. Additionally, increasing patient footfall in hospitals for diagnostics and treatments is contributing to the revenue growth of the segment. According to the International Diabetes Federation, in 2021, nearly 537 million adults were found to have diabetes, and it is estimated that there will be 783 million people worldwide with diabetes by 2045.
Diabetic Nephropathy Market by Region
Based on region, the global diabetic nephropathy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the global diabetic nephropathy market with the largest revenue share. The large revenue share of North America can be attributed to the increasing prevalence of diabetes, the growing geriatric population in the region, and increasing awareness about diabetic nephropathy. Additionally, the increasing number of prediabetic cases, favorable reimbursement policies, and growing numbers of approved drugs are supporting the revenue growth of the North American diabetic nephropathy market.
Asia Pacific’s diabetic nephropathy market is expected to show exceptional revenue growth during the forecast period owing to increasing diabetes cases and growing awareness.
Competitive Landscape
The prominent players operating in the global diabetic nephropathy market are:
Strategic Developments
North America and Asia Pacific are the key growth regions in the global diabetic nephropathy market.
The increasing prevalence of diabetes and rising investment in research and development are the key factors driving the revenue growth of the global diabetic nephropathy market.
The global diabetic nephropathy market is expected to register a revenue CAGR of 4.30% during the forecast period.
The estimated market size of the global diabetic nephropathy market is US$ 3.25 billion in 2030.
Janssen Pharmaceuticals, Inc., AstraZeneca, Aurobindo Pharma Limited, Bristol Myers Squibb Company, Bayer AG, and Merck & Co are among the key players operating in the global diabetic nephropathy market.
*Insights on financial performance are subject to the availability of information in the public domain